NO-prednisolone

CAS No. 327610-87-7

NO-prednisolone( —— )

Catalog No. M33613 CAS No. 327610-87-7

NO-prednisolone (NCX-1015) is a compound that effectively stimulates the production of IL-10 in vivo. It is a Prednisolone derivative that releases nitric oxide (NO).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 125 In Stock
5MG 105 In Stock
10MG 164 In Stock
25MG 297 In Stock
50MG 414 In Stock
100MG 581 In Stock
200MG 768 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NO-prednisolone
  • Note
    Research use only, not for human use.
  • Brief Description
    NO-prednisolone (NCX-1015) is a compound that effectively stimulates the production of IL-10 in vivo. It is a Prednisolone derivative that releases nitric oxide (NO).
  • Description
    NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone.NO-prednisolone potently stimulates IL-10 production in vivo.
  • In Vitro
    NO-prednisolone (NCX-1015), an NO-releasing derivative of Prednisolone, is demonstrated to be more effective than Prednisolone in reducing inflammation, inhibiting cytokine and chemokine generation, and up-regulating the expression of the steroid-sensitive cell-surface marker CD163 in human peripheral blood mononuclear cellsIncubation of PBMCs with NO-prednisolone (NCX-1015) and Prednisolone produces a concentration-dependent activation of CD163. NO-prednisolone is more potent than Prednisolone at inducing CD163 cell surface expression. The increased efficacy of NO-prednisolone, compared with the parent molecule Prednisolone, is also observed when assessing inhibition of LPS induced IL-1β production.
  • In Vivo
    In vivo treatment with NO-prednisolone (NCX-1015) potently stimulates IL-10 production, suggesting that the NO steroid induces a regulatory subset of T cells that negatively modulates intestinal inflammation. The two doses of NO-prednisolone tested, 0.5 and 5 mg/kg/day (equivalent to 0.33 and 3.3 mg/kg/day prednisone, respectively) effectively attenuates the severity of the wasting syndrome, ameliorates the colitis score, and reduces the colonic myeloperoxidase (MPO) activity. NO-prednisolone administration also reduces the colonic mRNA and protein content of tumor necrosis factor-α, IL-12, and IFN-γ. NO-prednisolone also reduces the expression of inducible NO synthase and cyclooxygenase-2 but in contrast does not inhibit colonic expression of IL-10 mRNA or protein. In fact, IL-10 expression is enhanced in mice treated with NO-prednisolone.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    327610-87-7
  • Formula Weight
    539.57
  • Molecular Formula
    C29H33NO9
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (46.33 mM; Ultrasonic (<60°C)
  • SMILES
    [H][C@@]12CC[C@](O)(C(=O)COC(=O)c3ccc(CO[N+]([O-])=O)cc3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fiorucci S, et al. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15770-?
molnova catalog
related products
  • YM-90709

    A potent IL-5 receptor antagonist that inhibits the binding of IL-5 to its receptor on peripheral human eosinophils and butyric acid-treated eosinophilic HL-60 clone 15 cells with IC50 of 1.0 and 0.57 uM, respectively.

  • Risankizumab

    Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.

  • IL-2-IN-1

    IL-2-IN-1 is a potent inhibitor of IL-2 (IC50: 1978 nM) and demonstrates anti-proliferative effects.